Predictive factors and clinical biomarkers for treatment in patients with chronic pain caused by osteoarthritis with a central sensitisation component

• Published in: International journal of clinical practice (Esher) Vol. 70; no. 1; pp. 31 - 44
• Main Authors: Akinci, A., Al Shaker, M., Chang, M. H., Cheung, C. W., Danilov, A., José Dueñas, H., Kim, Y. C., Guillen, R., Tassanawipas, W., Treuer, T., Wang, Y.
• Format: Journal Article
• Language: English
• Published: India Blackwell Publishing Ltd 01.01.2016; Hindawi Limited; John Wiley and Sons Inc
• Subjects: Arthritis; Biomarkers; Central Nervous System Sensitization; Chronic Pain - etiology; Chronic Pain - physiopathology; Chronic Pain - therapy; Combined Modality Therapy; Functional Neuroimaging; Humans; Magnetic Resonance Imaging; Nociception; Osteoarthritis - complications; Osteoarthritis - physiopathology; Osteoarthritis - therapy; Pain Measurement; Review; Risk Factors
• ISSN: 1368-5031; 1742-1241
• DOI: 10.1111/ijcp.12749

Summary Aims The aim of this non‐systematic review was to provide a practical guide for clinicians on the evidence for central sensitisation in chronic osteoarthritis (OA) pain and how this pain mechanism can be addressed in terms of clinical diagnosis, investigation and treatment. Methods The authors undertook a non‐systematic review of the literature including a MEDLINE search (search terms included central sensitisation, osteoarthritis, osteoarthrosis) for relevant and current clinical studies, systematic reviews and narrative reviews. Case reports, letters to the editor and similar literature sources were excluded. Information was organised to allow a pragmatic approach to the discussion of the evidence and generation of practical recommendations. Results There is good evidence for a role of central sensitisation in chronic OA pain in a subgroup of patients. Clinically, a central sensitisation component in chronic OA pain can be suspected based on characteristic pain features and non‐pain features seen in other conditions involving central sensitisation. However, there are currently no diagnostic inventories for central sensitisation specific to OA. Biomarkers may be helpful for confirming the presence of central sensitisation, especially when there is diagnostic uncertainty. Several non‐pharmacological and pharmacological treatments may be effective in OA patients with central sensitisation features. Multimodal therapy may be required to achieve control of symptoms. Discussion Clinicians should be aware of central sensitisation in patients with chronic OA pain, especially in patients presenting with severe pain with unusual features.